George Cockerill

This inventor holds 9 USPTO granted patents. Top assignees: Glaxo Group Limited, Astrazeneca Ab. Active years: 2006-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George Cockerill. Retrieved from https://idiyas.com/inventor/george-cockerill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

Average Co-Inventor Count = 6.4

ph-index = 7

Forward Citations = 82(Granted Patents)

Company Filing History:

Years Active: 2006-2011

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8039616 - Benzodiazepine derivatives for treating hepatitis C infection (2011-10-18),

2. 7432289 - 5-Acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors (2008-10-07),

3. 7396843 - 5'-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2008-07-08),

4. 7384963 - 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase (2008-06-10),

5. 7309800 - Biphenylcarboxylic amide derivatives as p38 kinase inhibitors (2007-12-18),

6. 7208629 - 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2007-04-24),

7. 7183297 - Biphenyl-derivatives as p38-kinase inhibitors (2007-02-27),

8. 7166623 - 2'-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors (2007-01-23),

9. 7151118 - Biphenylcarboxylic amide derivatives as p38-kinase inhibitors (2006-12-19),

Title: George Cockerill: Innovator in Pharmaceutical Chemistry

Introduction

George Cockerill is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical treatments. With a total of 9 patents to his name, Cockerill's work has had a substantial impact on the industry.

Latest Patents

Cockerill's latest patents include groundbreaking research on benzodiazepine derivatives for treating hepatitis C infection. This patent focuses on the use of a specific benzodiazepine formula in the manufacture of a medicament aimed at treating or preventing hepatitis C. Additionally, he has developed 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives, which serve as p38 kinase inhibitors, showcasing his expertise in creating pharmaceuticals that target critical pathways in disease processes.

Career Highlights

Throughout his career, Cockerill has worked with prominent companies such as Glaxo Group Limited and AstraZeneca. His experience in these leading pharmaceutical firms has allowed him to refine his skills and contribute to significant advancements in drug development.

Collaborations

Cockerill has collaborated with esteemed colleagues, including Richard Angell and Paul Bamborough. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.

Conclusion

George Cockerill's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to influence the development of new treatments for various medical conditions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]